Novartis building
(Photo via Novartis)

Novartis on World Malaria Day 2021

Originally published at Novartis Pharmaceuticals is a DiversityInc Hall of Fame company.


The COVID-19 pandemic highlights the importance of robust health systems to respond to disease outbreaks and to control other deadly diseases such as malaria. On World Malaria Day, April 25, we are calling on the global health community to continue to uphold progress and commitments made in the fight to end malaria.

In 1999, Novartis launched the first fixed-dose Artemisinin-based Combination Therapy (ACT) and in 2009, the first dispersible pediatric ACT developed in partnership with Medicines for Malaria Venture (MMV). Over the past 20 years, together with our partners, we have delivered nearly 1 billion treatments, including over 430 million pediatric treatments to malaria-endemic countries.


Working on next-generation antimalarials

Novartis is advancing Research & Development of next-generation treatments to combat emerging drug resistance. We lead five malaria development programs worldwide, featuring three compounds that employ new mechanisms of action and activity against artemisinin-resistant strains of the disease. KAF156 belongs to a novel class of antimalarial compounds that act against both the blood and liver stages of the parasite’s lifecycle. It demonstrated activity against both vivax and falciparum malaria, including artemisinin-resistant parasites. Novartis leads the development of this compound with scientific and financial support from MMV in collaboration with the Bill & Melinda Gates Foundation.

KAE609 is another novel antimalarial compound demonstrating rapid clearance of parasites pre-clinically and in patients. Novartis is leading the development of KAE609 in collaboration with MMV and with financial support from the Wellcome Trust.

In 2020, we discovered another novel malaria therapy, INE963, which has an entirely new mechanism of action and is expected to begin clinical trials in 2021. INE963 is a fast-acting, long-lasting antimalarial that could potentially be delivered as a single-dose cure. It was discovered with support from MMV and received the organization’s “Project of the Year” award in 2020.

As part of the PAMAfrica research consortium led by Medicines for Malaria Venture, we also initiated the development of a new formulation of our ACT for infants weighing less than 5 kilograms. This is one of the most vulnerable groups affected by malaria, for whom there is currently no approved treatment.


R&D partnerships to combat drug-resistant malaria in Africa

The European & Developing Countries Clinical Trials Partnership (EDCTP) awarded a grant to the new PAMAfrica research consortium led by MMV. The consortium will support the development of new treatments for malaria in the most at-risk populations, including babies, patients with severe malaria, and those with drug-resistant infections. The EDCTP grant of EUR 21.9 million will be matched by funding from MMV, Novartis and partners.

Further, the EDCTP granted EUR 10 million over five years to the West African Network for Clinical Trials of Antimalarial Drugs, a collaboration between antimalarial drug researchers in Africa and Europe from 10 academic institutions, Novartis and MMV. The grant will support African trials of a combination comprising KAF156 and lumefantrine in a new once-daily formulation.


Closing the gap for children with malaria

Despite the tremendous progress made in combating malaria in the past two decades, one child still dies from the disease every two minutes. We are committed to contributing to the WHO’s target of reducing malaria-related child mortality by at least 90% in 2030 by bringing our medicines to these small patients as quickly as possible.

In Nigeria, we are working with partners to strengthen access to diagnosis and treatment at patent and proprietary medicine vendor (PPMV) shops for children under age 5 with malaria. We expect to expand to additional countries in Sub-Saharan Africa in the coming years.


Local insights and learnings are key to accelerating progress

Novartis commissioned opinion research studies in sub-Saharan and Central Africa, and in five countries in South and Southeast Asia to capture the views of malaria experts – from government, the research community and NGOs – on progress and challenges toward the 2030 global malaria goals.


To read the full reports, click here.

Latest News

woke politics

Republicans Launch a War on ‘Woke’ Politics in Hopes of Big Legislative Wins in 2022

In 2020, former President Barack Obama warned that the phrase “Defund the Police” could become a dangerous rallying cry for the conservative right. But now, Republicans have apparently taken that warning one step further, declaring war on all things “woke.” Allan Smith and Sahil Kapur of NBC News wrote that…

women in politics

Women Remain Vastly Underrepresented in Local Government, Despite Conventional Wisdom Suggesting Otherwise

Vice President Kamala Harris and Speaker of the House Nancy Pelosi sat behind President Biden during his first speech to a joint session of Congress on April 28 — representing the first time two women held such important and high-ranking political offices. Even after such a historic moment, the reality…

voter restriction

Florida Follows Georgia’s Lead, Approves Racist Anti-Voter Restrictions Aimed Primarily at Democrats and People of Color

Not content with letting Georgia be the only state in the South demonized for its bigoted and racist attacks on voter rights, Florida has jumped into the fray in issuing its own series of new and highly controversial “Jim Crow-esque” anti-voting restrictions aimed specifically at disenfranchising Democrats and voters of…

Kentucky Derby

Inspired by Protests Over Breonna Taylor’s Death, Humana and Kentucky Derby Festival Launch Diversity and Inclusion Initiative in Louisville

Ahead of the 147th Kentucky Derby on Saturday, May 1, Kentucky Derby officials and Humana (No. 25 on The DiversityInc Top 50 Companies for Diversity list in 2020) have announced a new equity initiative meant to make the race more accessible and welcoming to everyone, regardless of race, gender, age…

crimes against human ity

‘Crime Against Humanity’; Global Report Says the US Should Be Prosecuted in International Criminal Court for Ongoing Police Murders of Black Americans

In what has been described as a “devastating” report, human rights experts and lawyers have investigated and released a 188-page analysis of the ongoing police brutality and killing of Black Americans in the U.S. Their verdict: the country is guilty of “crimes against humanity” and should be prosecuted for its…

Tokyo, Olympics

Tokyo Olympics to Encourage Significant Increase in Gender Equality Among Event’s Corporate Sponsors

Besides simply being a showcase for some of the most talented and athletic men and women on the planet, the organizers of the Tokyo Olympics are hoping their event this summer can also help promote significant change in corporate culture, both in Japan and around the globe. Bloomberg’s Ayai Tomisawa…